REACT for Chronic Kidney Disease in Diabetics
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial is testing REACT injections, which are given directly into the kidneys, to help patients with diabetes and chronic kidney disease. The goal is to see if these injections can improve kidney function.
Who Is on the Research Team?
Catherine Taylor
Principal Investigator
Prokidney
Are You a Good Fit for This Trial?
This trial is for men and women aged 30-80 with Type 1 or Type 2 Diabetes and Chronic Kidney Disease (CKD). Participants should have diabetic nephropathy, an eGFR of 20-50 mL/min/1.73m² without needing dialysis, controlled diabetes, and HbA1c levels below 10%. Excluded are those with renal transplants, uncontrolled blood pressure despite medication, or hemoglobin levels under 10 g/dL not improved by standard treatments.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive up to two REACT injections delivered percutaneously into biopsied and non-biopsied contralateral kidneys
Follow-up
Participants are monitored for safety and effectiveness after treatment
Long-term monitoring
Participants are monitored for changes in renal function and other health parameters
What Are the Treatments Tested in This Trial?
Interventions
- REACT®
Find a Clinic Near You
Who Is Running the Clinical Trial?
Prokidney
Lead Sponsor